1984
DOI: 10.1128/iai.45.2.350-355.1984
|View full text |Cite
|
Sign up to set email alerts
|

Influence of fine structure of lipid A on Limulus amebocyte lysate clotting and toxic activities

Abstract: We examined the relationship between the fine structure of lipid A and the toxicity of endotoxin or lipopolysaccharides as measured by the Limulus amebocyte lysate (LAL), rabbit pyrogenicity, chicken embryo lethal dose, and dermal Shwartzman reaction tests. Lipid A and lipid Alike compounds obtained from deeprough mutants of Salmonella spp. and Escherichia coli had a wide range of structural variations. These compounds included native lipopolysaccharides, diphosphoryl and monophosphoryl lipid A's, and lipid X … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

2
35
0
1

Year Published

1986
1986
2013
2013

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 101 publications
(38 citation statements)
references
References 25 publications
2
35
0
1
Order By: Relevance
“…The 4'-monophosphate analog of compound 516, compound 514, was weaker than compound 516 in all of the assay systems, except immunoadjuvant activity against BSA in mice, which was examined with liposomes as the administration vehicle. This finding is consistent with our previous observation that synthetic lipid A analogs of compound series 400 and 500, lacking a phosphate group at the C-1 position (compounds 404 and 504), exhibited weaker activities than the respective 1,4'-bisphosphate compound (18,20,35) and is in accord with the observations by Qureshi et al (28) and Takayama et al (36) with bacterial products, i.e., that 4'-monophosphoryl lipid A isolated from the lipid A fraction of Salmonella typhimurium, whose chemical structure corresponds to that of compound 504, was nontoxic. The lower biological activity of R595 lipid A than compound 506 may also be explained by the fact that this bacterial product contains compounds of 4'-monophosphate structure.…”
Section: Resultssupporting
confidence: 94%
“…The 4'-monophosphate analog of compound 516, compound 514, was weaker than compound 516 in all of the assay systems, except immunoadjuvant activity against BSA in mice, which was examined with liposomes as the administration vehicle. This finding is consistent with our previous observation that synthetic lipid A analogs of compound series 400 and 500, lacking a phosphate group at the C-1 position (compounds 404 and 504), exhibited weaker activities than the respective 1,4'-bisphosphate compound (18,20,35) and is in accord with the observations by Qureshi et al (28) and Takayama et al (36) with bacterial products, i.e., that 4'-monophosphoryl lipid A isolated from the lipid A fraction of Salmonella typhimurium, whose chemical structure corresponds to that of compound 504, was nontoxic. The lower biological activity of R595 lipid A than compound 506 may also be explained by the fact that this bacterial product contains compounds of 4'-monophosphate structure.…”
Section: Resultssupporting
confidence: 94%
“…Cyanobacteria contain not only different amounts of LPS, but also their endotoxin activity differs substantially. Further research should therefore focus on the structural variability of cyanobacterial LPS, particularly lipid A, which is the major component responsible for endotoxin activities in the LAL-test (Takayama et al, 1984).…”
Section: Discussionmentioning
confidence: 99%
“…The gelation times of 5, 10 and 20 pg ml −1 MPLA were 42·6, 32·3 and 25·9 min, respectively, and the activity ratio of MPLA relative to lipid A was 23·1% (Table ), which was lower than that previously reported (Takayama et al . ; Johnson et al . ).…”
Section: Resultsmentioning
confidence: 99%